Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer

BACKGROUND: Crizotinib, an ATP-competitive receptor tyrosine kinase inhibitor of both anaplastic lymphoma kinase (ALK) and the hepatocyte growth factor receptor, commonly causes several adverse events (AEs). The clinical utility of measuring the plasma concentration of crizotinib in patients with no...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurata, Yasuko, Miyauchi, Narumi, Suno, Manabu, Ito, Takahiro, Sendo, Toshiaki, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728826/
https://www.ncbi.nlm.nih.gov/pubmed/26819719
http://dx.doi.org/10.1186/s40780-014-0008-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728826/
https://www.ncbi.nlm.nih.gov/pubmed/26819719
http://dx.doi.org/10.1186/s40780-014-0008-x

Ejemplares similares